Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Smith

Showing results (81-90 of 168) with videos related to

Pageof 17
Sort By:
Clinical Genitourinary Cancer|July 25, 2007
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinomaNiklas J Mackler, Kenneth J Pienta, Rodney L Dunn, et al.
American Journal of Clinical Oncology|April 7, 2007
The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplantMerideth M M Wendland, David C Smith, Kenneth M Boucher, et al.
The Journal of Urology|April 18, 2009
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)Ralph W deVere White, Primo N Lara, Bryan Goldman, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2013
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528Shirish M Gadgeel, Danika L Lew, Timothy W Synold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumorsDavid C Smith, Peter D Eisenberg, Georgy Manikhas, et al.
Nanoscale Advances|September 22, 2022
Confining the growth of mesoporous silica films into nanospaces: towards surface nanopatterningSamantha Soulé, Gilles E Moehl, Ruomeng Huang, et al.
FEMS Microbiology Ecology|January 31, 2013
Targeted search for actinomycetes from nearshore and deep-sea marine sedimentsAlejandra Prieto-Davó, Luis J Villarreal-Gómez, Stephanie Forschner-Dancause, et al.
Investigational New Drugs|September 20, 2018
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumorsAntonio Jimeno, Kathleen N Moore, Michael Gordon, et al.
Cancer|May 21, 2011
Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approachAjjai S Alva, Christopher T Tallman, Chang He, et al.
Cancer|June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 studyDavid J Vaughn, Sandy Srinivas, Walter M Stadler, et al.
Pageof 17

Showing results (81-90 of 168) with videos related to

Sort By:
Pageof 17
Clinical Genitourinary Cancer|July 25, 2007
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinomaNiklas J Mackler, Kenneth J Pienta, Rodney L Dunn, et al.
American Journal of Clinical Oncology|April 7, 2007
The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplantMerideth M M Wendland, David C Smith, Kenneth M Boucher, et al.
The Journal of Urology|April 18, 2009
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)Ralph W deVere White, Primo N Lara, Bryan Goldman, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2013
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528Shirish M Gadgeel, Danika L Lew, Timothy W Synold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2014
A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumorsDavid C Smith, Peter D Eisenberg, Georgy Manikhas, et al.
Nanoscale Advances|September 22, 2022
Confining the growth of mesoporous silica films into nanospaces: towards surface nanopatterningSamantha Soulé, Gilles E Moehl, Ruomeng Huang, et al.
FEMS Microbiology Ecology|January 31, 2013
Targeted search for actinomycetes from nearshore and deep-sea marine sedimentsAlejandra Prieto-Davó, Luis J Villarreal-Gómez, Stephanie Forschner-Dancause, et al.
Investigational New Drugs|September 20, 2018
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumorsAntonio Jimeno, Kathleen N Moore, Michael Gordon, et al.
Cancer|May 21, 2011
Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approachAjjai S Alva, Christopher T Tallman, Chang He, et al.
Cancer|June 19, 2009
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 studyDavid J Vaughn, Sandy Srinivas, Walter M Stadler, et al.
Pageof 17